Erasca Stock Crashes on Patient Death — But Analysts Call the Selloff Overdone
Erasca stock fell after a patient died in a cancer drug trial. Analysts say it’s likely a rare case, drug still shows promise.
/ 8 items
#ERAS↓
Erasca Vows to Fight Revolution Medicines Patent Allegations – Stifel Stays Bullish
Erasca denies patent claims by Revolution Medicines, will fight back; Stifel keeps Buy rating.
Pancreatic Cancer Breakthrough: New Daily Pill Nearly Doubles Survival in Major Trial
New drug daraxonrasib from Revolution Medicines doubled survival in pancreatic cancer (13.2 vs 6.7 months) and cut death risk by 60% in Phase 3.
Merck Ends Talks to Buy Cancer Biotech Revolution Medicines in $30B Deal
Merck has walked away from negotiations to acquire Revolution Medicines after failing to agree on price for the promising cancer drug developer valued around $30 billion.
Merck Eyes $28-32 Billion Deal for Cancer Drugmaker Revolution Medicines
Merck negotiates potential acquisition of Revolution Medicines for up to $32B, seeking new cancer treatments as Keytruda patent expiration looms in 2028.
AbbVie Denies Acquisition Talks with Revolution Medicines Despite WSJ Report
AbbVie denies reports of buying Revolution Medicines after Wall Street Journal claimed advanced talks.